Abstract
68Ga-prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/ computer tomography (CT) is a promising diagnostic tool for patients with prostate cancer. Our study evaluates standardized uptake values (SUV) in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred and four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. Maximum SUV (SUVmax) was measured and correlated with biopsy findings and magnetic resonance imaging (MRI). Afterwards, data was compared with current prostate specific antigen (PSA) values, Gleason score (GS) and d’Amico risk classification. Results: In this investigation a mean SUVmax of 1.88 ± 0.44 in healthy prostate tissue compared to 10.77 ± 8.45 in malignant prostate lesions (P < 0.001) was observed. Patients with higher PSA, higher GS and higher d’Amico risk score had statistically significant higher PSMA uptake on PET/CT (P < 0.001 each). Conclusion: PSMA-PET/CT is well suited for detecting the intraprostatic malignant lesion in patients with newly diagnosed prostate cancer. Our findings indicate a significant correlation of PSMA-uptake with PSA, GS and risk classification according to d’Amico scale.
- Genitourinary
- Molecular Imaging
- MRI
- Oncology: GU
- PET
- PET/CT
- Radiation Therapy Planning
- Gleason Score
- PSMA-PET/CT
- SUV
- prostate cancer
- radiotherapy
- Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.